FDA Recalls Cardioplegia Solution Due to Sterility Assurance Issues
Central Admixture Pharmacy Services is recalling Cardioplegia Solution due to FDA concerns about sterility assurance. The recall affects 52 bags distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II recall with no reported illnesses or injuries. Per the severity rubric, when illnesses or injuries are not reported and the hazard remains theoretical, the maximum score is 3. The High rating reflects the seriousness of sterility assurance in pharmaceutical products, though no contamination or patient harm has been documented.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling Cardioplegia Solution, Induction 4:1 Plasmalyte, packaged in 542 mL bags, due to lack of assurance of sterility. Following an FDA inspection, the agency questioned whether these products maintain the sterility they are intended to have.
The recall affects 52 bags distributed nationwide. The affected lot numbers and expiration dates are: 37-895217 (Exp 05/04/2023), 37-898803 (Exp 05/18/2023), and 37-900614 (Exp 05/25/2023). The product has NDC 71285-0212-1 and is manufactured by Central Admixture Pharmacy Services, Inc., located at 6580 Snowdrift Road, Allentown, PA 18106.
This is a Class II FDA recall. No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- Cardioplegia Solution, Induction 4:1 Plasmalyte, HIGH POTASSIUM, HIGH K, packaged in 542 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., Lehigh Valley, 6580 Snowdrift Road, Allentown, PA 18106, NDC 71285-0212-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # 37-895217
- Exp 05/04/2023
- 37-898803
- Exp 05/18/2023
- 37-900614
- Exp 05/25/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27